MGI Pharma RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifFinanzen.nethttp://www.finanzen.netEisai Completes Acquisition of MGI PHARMAhttp://www.finanzen.net/nachricht/aktien/Eisai-Completes-Acquisition-of-MGI-PHARMA-280012Eisai Co., Ltd. (Tokyo, TSE 4523) ("Eisai”), a research-based human health care (hhc) company, today announced the successful completion of its acquisition of MGI PHARMA, INC. (NASDAQ: MOGN) ("MGI PHARMA”) for approximately ...http://www.finanzen.net/nachricht/aktien/Eisai-Completes-Acquisition-of-MGI-PHARMA-280012Eisai Announces Completion of Tender Offer for MGI Pharma Shareshttp://www.finanzen.net/nachricht/aktien/Eisai-Announces-Completion-of-Tender-Offer-for-MGI-Pharma-Shares-279334Eisai Co., Ltd. (Tokyo, TSE 4523) ("Eisai”), a research-based human health care (hhc) company, today announced the completion of the offer by its indirect wholly-owned subsidiary, Jaguar Acquisition Corp. ("Jaguar”), to purchase ...http://www.finanzen.net/nachricht/aktien/Eisai-Announces-Completion-of-Tender-Offer-for-MGI-Pharma-Shares-279334Eisai Announces Satisfaction of Conditions to Tender Offer for MGI PHARMA Shareshttp://www.finanzen.net/nachricht/aktien/Eisai-Announces-Satisfaction-of-Conditions-to-Tender-Offer-for-MGI-PHARMA-Shares-277790Eisai Co., Ltd. (Tokyo, TSE 4523) ("Eisai”), a research-based human health care (hhc) company, today announced the satisfaction of all of the conditions to the offer by its indirect wholly-owned subsidiary, Jaguar Acquisition Corp. ...http://www.finanzen.net/nachricht/aktien/Eisai-Announces-Satisfaction-of-Conditions-to-Tender-Offer-for-MGI-PHARMA-Shares-277790MGI PHARMA Announces Results from Study Involving the Dual Implantation of Gliadel(R) Wafer and Radioactive Seeds for Treatment of Recurrent Glioblastoma Multiformehttp://www.finanzen.net/nachricht/aktien/MGI-PHARMA-Announces-Results-from-Study-Involving-the-Dual-Implantation-of-Gliadel-R-Wafer-and-Radioactive-Seeds-for-Treatment-of-Recurrent-Glioblastoma-Multiforme-276040MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that study results published in the February issue of the Journal of Neurosurgery show that treatment of patients who ...http://www.finanzen.net/nachricht/aktien/MGI-PHARMA-Announces-Results-from-Study-Involving-the-Dual-Implantation-of-Gliadel-R-Wafer-and-Radioactive-Seeds-for-Treatment-of-Recurrent-Glioblastoma-Multiforme-276040Eisai and MGI PHARMA Announce Early Termination of HSR Waiting Period for Eisai's Acquisition of MGI PHARMAhttp://www.finanzen.net/nachricht/aktien/Eisai-and-MGI-PHARMA-Announce-Early-Termination-of-HSR-Waiting-Period-for-Eisai-s-Acquisition-of-MGI-PHARMA-275411Eisai Co., Ltd. (Tokyo, TSE: 4523) ("Eisai”) and MGI PHARMA, INC. (NASDAQ: MOGN) ("MGI PHARMA”) announced today that the Federal Trade Commission has granted early termination of the statutory waiting period under the Hart-Scott-Rodino ...http://www.finanzen.net/nachricht/aktien/Eisai-and-MGI-PHARMA-Announce-Early-Termination-of-HSR-Waiting-Period-for-Eisai-s-Acquisition-of-MGI-PHARMA-275411Notice of Correction to Notice of Conversion Right for Senior Subordinated Convertible Notes Due 2024http://www.finanzen.net/nachricht/aktien/Notice-of-Correction-to-Notice-of-Conversion-Right-for-Senior-Subordinated-Convertible-Notes-Due-2024-270828On December 26, 2007, MGI PHARMA, INC. issued a Notice of Conversion Right to holders of its Senior Subordinated Convertible Notes due 2024. The notice incorrectly listed February 15, 2007 as the date after which any note surrendered ...http://www.finanzen.net/nachricht/aktien/Notice-of-Correction-to-Notice-of-Conversion-Right-for-Senior-Subordinated-Convertible-Notes-Due-2024-270828MGI PHARMA and HELSINN Announce sNDA for Aloxi Capsules Accepted for Review by U.S. FDAhttp://www.finanzen.net/nachricht/aktien/MGI-PHARMA-and-HELSINN-Announce-sNDA-for-Aloxi-Capsules-Accepted-for-Review-by-U-S-FDA-269410MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced that a supplemental New Drug Application ...http://www.finanzen.net/nachricht/aktien/MGI-PHARMA-and-HELSINN-Announce-sNDA-for-Aloxi-Capsules-Accepted-for-Review-by-U-S-FDA-269410Notice of Conversion Right for Senior Subordinated Convertible Notes Due 2024http://www.finanzen.net/nachricht/aktien/Notice-of-Conversion-Right-for-Senior-Subordinated-Convertible-Notes-Due-2024-268052MGI PHARMA, INC. (NASDAQ:MOGN) (the "Company” or "MGI PHARMA”), today announced that the Company’s Senior Subordinated Convertible Notes due 2024 (the "Notes”) shall become convertible as a result of the Company entering into ...http://www.finanzen.net/nachricht/aktien/Notice-of-Conversion-Right-for-Senior-Subordinated-Convertible-Notes-Due-2024-268052Eisai Commences Cash Tender Offer for All Outstanding Shares of MGI PHARMAhttp://www.finanzen.net/nachricht/aktien/Eisai-Commences-Cash-Tender-Offer-for-All-Outstanding-Shares-of-MGI-PHARMA-267758Eisai Co., Ltd. (Tokyo, TSE 4523), a research-based human health care (hhc) company, today announced the commencement of its cash tender offer for all outstanding shares of the common stock of MGI PHARMA, Inc. (NASDAQ: MOGN) for US$41.00 ...http://www.finanzen.net/nachricht/aktien/Eisai-Commences-Cash-Tender-Offer-for-All-Outstanding-Shares-of-MGI-PHARMA-267758MGI PHARMA Announces Aquavan NDA Accepted for Review by U.S. FDAhttp://www.finanzen.net/nachricht/aktien/MGI-PHARMA-Announces-Aquavan-NDA-Accepted-for-Review-by-U-S-FDA-265119MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care today announced that the New Drug Application (NDA) for Aquavan® (fospropofol disodium) Injection was accepted for filing by the United ...http://www.finanzen.net/nachricht/aktien/MGI-PHARMA-Announces-Aquavan-NDA-Accepted-for-Review-by-U-S-FDA-265119